Table 1. Overview of TEAEs and most common TEAEs following treatment with placebo or a single oral dose of perampanel 36-mg (occurring in ≥5% of participants in either treatment arm) during Study 024

	Placebo (n=36)	Perampanel 36 mg (n=37)
Any TEAEs, n (%)	11 (30.6)	37 (100)
Any treatment-related TEAE, n (%)	9 (25.0)	37 (100)
Any TEAE leading to study withdrawal, n (%)	0 (0.0)	2 (5.4)
Any SAE, n (%)	0 (0.0)	0 (0.0)
Most common (≥5%) TEAEs		
Somnolence	2 (5.6)	31 (83.8)
Dizziness	2 (5.6)	22 (59.5)
Euphoric mood	3 (8.3)	17 (45.9)
Fatigue	3 (8.3)	9 (24.3)
Nausea	3 (8.3)	6 (16.2)
Hypoaesthesia oral	0 (0.0)	6 (16.2)
Vision blurred	1 (2.8)	5 (13.5)
Dysarthria	0 (0.0)	4 (10.8)
Coordination abnormal	0 (0.0)	4 (10.8)
Ataxia	0 (0.0)	4 (10.8)
Gait disturbance	0 (0.0)	3 (8.1)
Vomiting	0 (0.0)	3 (8.1)
Headache	0 (0.0)	2 (5.4)
Visual impairment	0 (0.0)	2 (5.4)
Feeling hot	0 (0.0)	2 (5.4)
Balance disorder	0 (0.0)	2 (5.4)
Rash	0 (0.0)	2 (5.4)
Muscular weakness	0 (0.0)	2 (5.4)

SAE, serious adverse event; TEAE, treatment-emergent adverse event